Mainz Biomed N.V.
MYNZ
$1.59
-$0.02-1.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 660.00K | 777.00K | 894.00K | 922.20K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 660.00K | 777.00K | 894.00K | 922.20K | -- |
| Cost of Revenue | 214.60K | 266.90K | 319.20K | 340.50K | -- |
| Gross Profit | 445.40K | 510.10K | 574.80K | 581.60K | -- |
| SG&A Expenses | 11.50M | 12.33M | 13.15M | 14.74M | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.36M | 18.34M | 19.31M | 21.63M | -- |
| Operating Income | -16.70M | -17.56M | -18.42M | -20.70M | -- |
| Income Before Tax | -18.97M | -20.31M | -21.65M | -21.52M | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.97 | -20.31 | -21.65 | -21.52 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.97M | -20.31M | -21.65M | -21.52M | -- |
| EBIT | -16.70M | -17.56M | -18.42M | -20.70M | -- |
| EBITDA | -15.98M | -16.77M | -17.55M | -19.75M | -- |
| EPS Basic | -10.37 | -18.90 | -27.44 | -34.45 | -- |
| Normalized Basic EPS | -5.68 | -10.72 | -15.76 | -21.47 | -- |
| EPS Diluted | -10.37 | -18.90 | -27.44 | -34.45 | -- |
| Normalized Diluted EPS | -5.68 | -10.72 | -15.76 | -21.47 | -- |
| Average Basic Shares Outstanding | 9.04M | 6.46M | 3.87M | 2.97M | -- |
| Average Diluted Shares Outstanding | 9.04M | 6.46M | 3.87M | 2.97M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |